Embryonic stem cell therapy took a wild twist last week, when one of the first and strongest players withdrew from an ongoing embryonic stem cell-based clinical trial. After years of aggressive research and development in embryonic stem cell technology and treatment strategies, and initiating a clinical trial for spinal cord injury with fanfare, Geron, a Menlo Park, California company, de